Clinical Research Directory

Inclusion Criteria: * Diagnosed with histologically confirmed adenocarcinoma of the prostate based on core-biopsy within 1 year of study entry from TRUS * Clinical stages T1c to T2c * PSA \<20, within 6 months of study entry * Participants who are currently receiving Dutasteride (or have received it within the last 90 days) or Finasteride (or have received it within the last 30 days) must have a PSA of ≤ 10 * Gleason score ≤6, 3 + 4 = 7, or 4 + 3 = 7 * ECOG Performance Status 0-1 as documented within 3 months prior to study entry * Must have complete history and physical examination within 45 days of study entry and digital rectal examination of prostate within 180 days of study entry Exclusion Criteria: * Prior surgery (not including TURP), cryosurgery, radiofrequency ablation, chemotherapy or radiation for PCa * Prior or planned androgen deprivation or bilateral orchiectomy * Distant metastases, or clinically or pathologically involved lymph nodes confirmed by a CT scan within 365 days of study entry * Hip prosthesis, inflammatory bowel disease or connective tissue disorder such as active scleroderma or lupus * Individuals with a history of other malignancies are ineligible unless 1) they have been disease-free for at least 5 years OR 2) are deemed by the investigator to be at low risk for recurrence of that malignancy with no plans for adjuvant systemic chemotherapy and/or radiation therapy and have received overall principal investigator approval. * Individuals who have AIDS (CD4 \< 200 or an AIDS-defining illness) or are HIV positive and not on HAART therapy are ineligible. * Major medical or psychiatric illness * Individuals with any of the following conditions are excluded from this study: * Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months. * Transmural myocardial infarction within the last 6 months. * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration. * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration * History of Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects within the last 12 months